- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00773474
Lonafarnib in Metastatic Breast Cancer
A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OUTLINE: This is a multi-center study
Patients will be treated with lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
1 Cycle = 21 days of lonafarnib (plus the time required to recover from toxicity if encountered).
ECOG Performance Status 0-1
Life Expectancy: Not Specified
Hematopoietic:
- Platelets > 100 K/mm3
- Absolute Neutrophil Count (ANC) > 1.2 K/mm3
- Hemoglobin ≥ 9 g/dl
- Serum potassium ≥ 3.3 mmol/L
Hepatic:
- Aspartate transaminase (AST) ≤ 5.0 x ULN
- Alanine transaminase (ALT) ≤ 5.0 x ULN
- Total bilirubin < 1.5 x ULN
Renal:
- Calculated creatinine clearance (using Cockcroft-Gault formula) > 45 cc/min
Cardiovascular:
- No history of Torsades de Pointes, ventricular tachycardia, ventricular fibrillation or ventricular flutter
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Galesburg, Illinois, Verenigde Staten, 61401
- Medical & Surgical Specialists, LLC
-
-
Indiana
-
Bloomington, Indiana, Verenigde Staten, 47403
- Cancer Care Center of Southern Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
Lafayette, Indiana, Verenigde Staten, 47905
- Horizon Oncology Center
-
Lafayette, Indiana, Verenigde Staten, 47904
- Arnett Cancer Care
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Ireland Cancer Center - University Hospitals of Cleveland
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histological or cytological confirmed adenocarcinoma of the breast with locally advanced or metastatic disease.
- Must be able and willing to enroll in the companion study entitled "Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-03."
- Must have measurable disease per RECIST as evaluated by imaging within 28 days prior to registration for protocol therapy.
- Must be willing to not drink grapefruit juice for the duration of lonafarnib therapy.
- Previously radiated area(s) must not be the only site of disease for study entry.
- Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time of consent until at least 90 days following completion of study treatment.
- Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy. Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
- Females must not be breastfeeding.
- Written informed consent and HIPAA authorization for release of personal health information.
- Age > 18 years
Exclusion Criteria:
- No history or radiologic evidence of CNS metastases including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement (head CT or MRI must be obtained within 42 days prior to registration for protocol therapy).
- No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
- No history of Torsades de Pointes, ventricular tachycardia, ventricular fibrillation or ventricular flutter.
- No history of syncope.
- No history of seizures.
- No prolonged QTc interval > 450msec on pre-entry electrocardiogram obtained within 28 days prior to registration for protocol therapy.
- No history of hypokalemia that cannot be corrected prior to registration for protocol therapy.
- No radiation within 14 days prior to registration for protocol therapy. Patients must have recovered from the acute toxic effects prior to registration for protocol therapy.
- No prior chemotherapy within 21 days prior to registration for protocol therapy.
- No clinically active serious infections as judged by the treating investigator (CTC v3, > Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- Following concomitant medications must be discontinued 7 days prior to registration for protocol therapy and for the duration of lonafarnib therapy: bisphosphonates, including but not limited to etidronate (Didronel), pamidronate (Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate (Zometa or Reclast), ibandronate (Boniva), ethinylestradiol, gestodene, itraconazole, ketoconazole, cimetidine, erythromycin, carbamazepine, high dose chronic steroids, phenobarbital, phenytoin, rifampin (rifampicin), sulfinpyrazone
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Lonafarnib
All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
|
All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression Free Survival
Tijdsspanne: 18 months
|
To determine progression-free survival of lonafarnib in patients with metastatic breast cancer.
|
18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Response Rate
Tijdsspanne: 18 months
|
To determine overall response rate.
|
18 months
|
Toxicity Profile of Lonafarib
Tijdsspanne: 18 months
|
To determine the toxicity profile of lonafarnib in this patient population.
|
18 months
|
Clinical Benefit Response Rate (Complete Response (CR)+Partial Response(PR)+Stable Disease(SD) > 180 Day Duration).
Tijdsspanne: 18 months
|
18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: George Sledge, M.D., Hoosier Cancer Research Network
- Hoofdonderzoeker: Brian Leland-Jones, M.D., Hoosier Cancer Research Network
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HOG BRE07-126
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Uitgezaaide borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Lonafarnib
-
Merck Sharp & Dohme LLCBeëindigdMetastasen, neoplasma | Carcinoom, niet-kleincellige long
-
Boston Children's HospitalAanmelden op uitnodiging
-
Eiger BioPharmaceuticalsGoedgekeurd voor marketing
-
National Institute of Diabetes and Digestive and...Voltooid
-
M.D. Anderson Cancer CenterVoltooidMyeloïde leukemie, chronischVerenigde Staten
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)VoltooidHersenen en tumoren van het centrale zenuwstelselVerenigde Staten
-
Monica E. KleinmanSchering-PloughVoltooidProgeria | Hutchinson-Gilford-syndroomVerenigde Staten
-
M.D. Anderson Cancer CenterSchering-PloughVoltooidCarcinoom, plaveiselcel | Hoofd-halskankerVerenigde Staten
-
Boston Children's HospitalMerck Sharp & Dohme LLC; Schering-Plough; Eiger BioPharmaceuticalsActief, niet wervendProgeriaVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)IngetrokkenColorectale kanker | Uitgezaaide kanker